Evaluating the Effect of Blue m Gel on Healing of Palatal Donor Site Versus Using Diode Laser

June 13, 2026 updated by: Delta University for Science and Technology
A sample size of 40 patients, Group A of 20 patients treated with blue m gel and Group B of 20 patient treated with diode laser were included in this study after free gingival grafts harvested from the hard palate. Participants were assessed for the amount and duration of bleeding, pain duration, and the risk of infection 2, 7,14, 30 days post-operative

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Dakhalia
      • Gamasa, Dakhalia, Egypt, 35516
        • Delta University For Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

- healthy

Exclusion Criteria:

  • smokers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: blue m gel group
application of blue m gel
Procedure: Blueb m gel
application of blue m oxygen releasing oral gel to the palate after free gingival graft
Experimental: laser group
application of laser
Procedure: Laser therapy
Application of Low level laser therapy to the Paltal donor site after free gingival graft harvesting

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pain intensity
Time Frame: one month
visual analogue scale
one month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bleeding time
Time Frame: One week
Presence or absence of bleeding
One week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Delta University for Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2025

Primary Completion (Actual)

December 31, 2025

Study Completion (Actual)

February 1, 2026

Study Registration Dates

First Submitted

June 9, 2026

First Submitted That Met QC Criteria

June 13, 2026

First Posted (Actual)

June 16, 2026

Study Record Updates

Last Update Posted (Actual)

June 16, 2026

Last Update Submitted That Met QC Criteria

June 13, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DU025052214

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Laser

Clinical Trials on Blueb m gel

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe